Nature Communications (May 2020)
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
- Jennifer Y. Ge,
- Shaokun Shu,
- Mijung Kwon,
- Bojana Jovanović,
- Katherine Murphy,
- Anushree Gulvady,
- Anne Fassl,
- Anne Trinh,
- Yanan Kuang,
- Grace A. Heavey,
- Adrienne Luoma,
- Cloud Paweletz,
- Aaron R. Thorner,
- Kai W. Wucherpfennig,
- Jun Qi,
- Myles Brown,
- Piotr Sicinski,
- Thomas O. McDonald,
- David Pellman,
- Franziska Michor,
- Kornelia Polyak
Affiliations
- Jennifer Y. Ge
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Shaokun Shu
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Mijung Kwon
- Department of Pediatric Oncology, Dana-Farber Cancer Institute
- Bojana Jovanović
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Katherine Murphy
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Anushree Gulvady
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Anne Fassl
- Department of Cancer Biology, Dana-Farber Cancer Institute
- Anne Trinh
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Yanan Kuang
- Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute
- Grace A. Heavey
- Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute
- Adrienne Luoma
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute
- Cloud Paweletz
- Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute
- Aaron R. Thorner
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Kai W. Wucherpfennig
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute
- Jun Qi
- Department of Medicine, Harvard Medical School
- Myles Brown
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Piotr Sicinski
- Department of Cancer Biology, Dana-Farber Cancer Institute
- Thomas O. McDonald
- Department of Data Sciences, Dana-Farber Cancer Institute
- David Pellman
- Department of Pediatric Oncology, Dana-Farber Cancer Institute
- Franziska Michor
- Department of Data Sciences, Dana-Farber Cancer Institute
- Kornelia Polyak
- Department of Medical Oncology, Dana-Farber Cancer Institute
- DOI
- https://doi.org/10.1038/s41467-020-16170-3
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 17
Abstract
Effective combination therapies to improve the efficacy of BET inhibitors are currently under investigation. Here, the authors examine palbociclib and paclitaxel as two promising candidates for combination therapies with BET inhibition in breast cancer and investigate the dynamics of resistance to these combinations through DNA barcoding and mathematical modelling.
